<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859869</url>
  </required_header>
  <id_info>
    <org_study_id>M16-142</org_study_id>
    <nct_id>NCT03859869</nct_id>
  </id_info>
  <brief_title>A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)</brief_title>
  <official_title>Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to
      pancreatic cancer that has been resected. This study will include resected participants who
      are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">December 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in stool for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 1 (Day 8)</time_frame>
    <description>Change in stool fat for Resected Dose A and Resected Dose B. Stool fat change is assessed using a paired t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between Resected Dose A and Resected Dose B in change from baseline in stool fat</measure>
    <time_frame>From Baseline (Day 1) to Week 1</time_frame>
    <description>Change from baseline in stool fat will be analyzed using an analysis of covariance model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Stool frequency is a patient reported outcome recorded using an electronic diary (eDiary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between Resected Dose A and Resected Dose B in change from baseline in stool frequency</measure>
    <time_frame>From Baseline (Day 1) to Week 1</time_frame>
    <description>Difference between Resected Dose A and Resected Dose B in change in stool frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Stool consistency is a patient reported outcome recorded using an electronic diary (eDiary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between Resected Dose A and Resected Dose B in change from baseline in stool consistency</measure>
    <time_frame>From Baseline (Day 1) to Week 1</time_frame>
    <description>Difference between Resected Dose A and Resected Dose B in change in stool consistency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exocrine pancreatic insufficiency (EPI) symptoms from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>EPI symptoms are patient reported outcomes recorded using an electronic diary (eDiary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between Resected Dose A and Resected Dose B in change from baseline in EPI symptoms</measure>
    <time_frame>From Baseline (Day 1) to Week 1</time_frame>
    <description>Difference between Resected Dose A and Resected Dose B in change in EPI symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) questionnaire from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Change in EORTC QOL questionnaire for Resected Dose A and Resected Dose B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between Resected Dose A and Resected Dose B in change in EORTC QOL questionnaire</measure>
    <time_frame>From Baseline (Day 1) to Week 1</time_frame>
    <description>Difference between Resected Dose A and Resected Dose B in change in EORTC QOL questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Change body weight for Resected Dose A and Resected Dose B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI) from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Change in body mass index (BMI) for Resected Dose A and Resected Dose B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy tolerability</measure>
    <time_frame>From Baseline (Day 1) up to Week 13</time_frame>
    <description>Chemotherapy tolerability will be evaluated through adverse events monitoring, physical examination, vital sign measurements, and laboratory testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Change in serum albumin for Resected Dose A and Resected Dose B. Low albumin levels can indicate a problem with your liver or kidneys.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum pre-albumin from baseline for Resected Dose A and Resected Dose B</measure>
    <time_frame>From Baseline (Day 1) to Week 5, Week 9, and Week 13</time_frame>
    <description>Change in serum pre-albumin for Resected Dose A and Resected Dose B. If pre-albumin levels are lower than normal, it may be a sign of poor nutrition.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Exocrine Pancreatic Insufficiency (EPI)</condition>
  <arm_group>
    <arm_group_label>Resected Participants Receiving Pancrelipase Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resected participants are administered with Pancrelipase dose A. At week 1,5, or 9, participants who meet dose modification criteria will be administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resected Participants Receiving Pancrelipase Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resected participants are administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Resected Participants Receiving Pancrelipase Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-resected participants are administered with Pancrelipase dose B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pancrelipase</intervention_name>
    <description>Pancrelipase is administered orally as capsules with a meal or snack</description>
    <arm_group_label>Non-Resected Participants Receiving Pancrelipase Dose B</arm_group_label>
    <arm_group_label>Resected Participants Receiving Pancrelipase Dose A</arm_group_label>
    <arm_group_label>Resected Participants Receiving Pancrelipase Dose B</arm_group_label>
    <other_name>Creon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered orally as capsule with a meal or snack</description>
    <arm_group_label>Resected Participants Receiving Pancrelipase Dose A</arm_group_label>
    <arm_group_label>Resected Participants Receiving Pancrelipase Dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has diagnosed cancer of pancreas with biopsy and/or radiography, with a
             life expectancy of at least 5 months at screening.

          -  Participant's pancreatic cancer must involve the head and/or neck of the pancreas.

          -  Confirmed EPI as evidenced by fecal elastase-1 (FE-1) &lt;= 150 microgram/gram stool at
             screening.

          -  A positive Sudan stain for participants without history of fat malabsorption (fat
             malabsorption is defined as clinical steatorrhea, or measured stool fat &gt; 7 g/day, or
             positive stool results by Sudan stain) within 1 week of screening.

               -  Positive stool results are defined as increased level of neutral OR total fats.

        Exclusion Criteria:

          -  Participant has neuroendocrine pancreatic cancer.

          -  Participant has fibrosing colonopathy

          -  Participant has any other malignancy within 1 year of screening.

          -  Participant has uncontrolled gout, including those with a recent flare within 60 days
             of screening.

          -  participant has other significant organ or bone marrow abnormality within 60 days of
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology /ID# 207770</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35223-2437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Banner University MC Phoenix /ID# 208402</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Fresno Center for Medical Education and Research /ID# 205757</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701-2302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center - LaJolla /ID# 202678</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Med /ID# 208821</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates /ID# 203363</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037-3201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida - Archer /ID# 202679</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute /ID# 211394</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904-8915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Community Hospital /ID# 202270</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005-2355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem - Evanston Hospital /ID# 209026</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hosp /ID# 203962</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center /ID# 203132</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453-2600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals /ID# 204407</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital /ID# 203449</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075-4825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis University School of Medicine /ID# 205769</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health Center for Liver Diseases /ID# 207321</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030-3815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital /ID# 207513</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University Langone Me /ID# 202290</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center /ID# 204165</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Carolina University /ID# 206661</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research /ID# 208030</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State Cancer Center /ID# 203131</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center /ID# 202288</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny Center Digestive Health /ID# 202291</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reading Hospital /ID# 206869</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Musc /Id# 210727</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists /ID# 208235</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Med Ctr /ID# 204231</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 206156</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center /ID# 202271</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>WI Center for Advanced Res /ID# 205746</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin /ID# 205714</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auxilio Mutuo Cancer Center /ID# 203129</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency (EPI)</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Creon</keyword>
  <keyword>Pancrelipase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

